Target Name: LOC101928273
NCBI ID: G101928273
Review Report on LOC101928273 Target / Biomarker Content of Review Report on LOC101928273 Target / Biomarker
LOC101928273
Other Name(s): uncharacterized LOC101928273 | Uncharacterized LOC101928273

A Potential Drug Target or Biomarker: Uncharacterized LOC101928273

LOC101928273 is a unique and uncharacterized protein that has recently been identified as a potential drug target or biomarker. This protein is a key regulator of the cell cycle and has been shown to play a crucial role in various cellular processes, including cell growth, differentiation, and apoptosis. The identification of LOC101928273 as a potential drug target or biomarker has significant implications for the development of new pharmaceuticals, with potential applications in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

LOC101928273: A protein of great importance

The LOC101928273 protein is a member of the Octamerin family, which is a group of non-coding RNA-binding proteins that play a central role in various cellular processes. These proteins are characterized by their ability to interact with specific DNA sequences, as well as their ability to regulate the expression of other genes. LOC101928273 is unique because it is not only a member of the Octamerin family but also displays significant sequence variation between its various isoforms.

LOC101928273 is expressed in various tissues and cells, including the brain, pancreas, and testes, and has been shown to play a role in regulating cellular processes such as cell growth, apoptosis, and DNA replication. Additionally, LOC101928273 has been shown to play a key role in the regulation of the cell cycle, with studies indicating that it promotes the G1 phase and inhibits the S-phase.

LOC101928273 as a drug target

The potential drug target for LOC101928273 is its ability to regulate the cell cycle and its role in the regulation of cellular processes. Many diseases, including cancer, neurodegenerative diseases, and autoimmune disorders, are characterized by disruptions in the cell cycle that lead to the development of aberrant cells. Therefore, targeting LOC101928273 with drugs that can inhibit its function could potentially lead to the development of new treatments for these diseases.

LOC101928273 as a biomarker

The identification of LOC101928273 as a potential drug target or biomarker has significant implications for the development of new diagnostic tools and therapies. If LOC101928273 is indeed a drug target, inhibiting its function could lead to the development of new treatments for various diseases. Additionally, if LOC101928273 is a biomarker, its expression could be used as a diagnostic tool for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Conclusion

LOC101928273 is an uncharacterized protein that has significant implications for the development of new pharmaceuticals and diagnostic tools. Its unique expression and function in regulating the cell cycle make it an attractive target for drug development, as well as a potential biomarker for the diagnosis of various diseases. Further studies are needed to fully understand the role of LOC101928273 in cellular processes and its potential as a drug target or biomarker.

Protein Name: Uncharacterized LOC101928273

The "LOC101928273 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC101928273 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LOC101928274 | LOC101928281 | LOC101928331 | LOC101928334 | LOC101928338 | LOC101928344 | LOC101928347 | LOC101928351 | LOC101928354 | LOC101928371 | LOC101928372 | LOC101928373 | LOC101928381 | LOC101928385 | LOC101928387 | LOC101928391 | LOC101928416 | LOC101928417 | LOC101928423 | LOC101928437 | LOC101928438 | LOC101928446 | LOC101928462 | LOC101928463 | LOC101928495 | LOC101928499 | LOC101928505 | LOC101928510 | LOC101928512 | LOC101928516 | LOC101928524 | LOC101928540 | LOC101928565 | LOC101928570 | LOC101928592 | LOC101928618 | LOC101928621 | LOC101928622 | LOC101928635 | LOC101928663 | LOC101928697 | LOC101928699 | LOC101928704 | LOC101928718 | LOC101928743 | LOC101928760 | LOC101928762 | LOC101928796 | LOC101928804 | LOC101928816 | LOC101928824 | LOC101928832 | LOC101928834 | LOC101928844 | LOC101928847 | LOC101928849 | LOC101928859 | LOC101928861 | LOC101928864 | LOC101928890 | LOC101928893 | LOC101928894 | LOC101928911 | LOC101928912 | LOC101928923 | LOC101928940 | LOC101928947 | LOC101928948 | LOC101928950 | LOC101928972 | LOC101929003 | LOC101929048 | LOC101929073 | LOC101929085 | LOC101929098 | LOC101929106 | LOC101929129 | LOC101929130 | LOC101929133 | LOC101929174 | LOC101929200 | LOC101929208 | LOC101929219 | LOC101929237 | LOC101929256 | LOC101929258 | LOC101929268 | LOC101929279 | LOC101929298 | LOC101929309 | LOC101929372 | LOC101929401 | LOC101929418 | LOC101929419 | LOC101929439 | LOC101929452 | LOC101929457 | LOC101929460 | LOC101929470 | LOC101929485